Significant revisions since the last chapter update are highlighted in the Canadian Immunization Guide (CIG) Table of Updates.
For additional information, refer to previously published National Advisory Committee on Immunization (NACI) Statements and Statement Updates.
Meningococcal disease is caused by an aerobic encapsulated diplococcus, N. meningitidis (meningococcus). Meningococcal serogroups are classified according to the immunologic reactivity of the polysaccharide capsule. Almost all invasive meningococcal disease (IMD) is associated with serogroups A, B, C, Y, and W-135. Meningococcal serogroups A, B, and C cause the majority of disease worldwide and are responsible for most sporadic cases and outbreaks. For further information about Neisseria meningitidis, refer to the Public Health Agency of Canada (PHAC) website.
Humans are the only reservoir for N. meningitidis.
Meningococci are transmitted person-to-person by mucosal contact with respiratory droplets from the nose and throat of infected persons. Most people who are colonized with meningococci are asymptomatic carriers.
Risk factors for the development of IMD include: complement, properdin or factor D deficiencies; functional or anatomic asplenia, including sickle cell disease; certain genetic risk factors (e.g. polymorphisms in the genes for mannose-binding lectin and tumor necrosis factor); household exposure to an infected person; concurrent respiratory tract infection; recent infection with influenza; household crowding; and active and passive smoking. Persons with HIV infection may be at increased risk for meningococcal disease, especially if HIV is congenitally acquired.
Seasonal and temporal patterns
Although disease occurs year-round, there is seasonal variation, with the majority of cases occurring in the winter and spring period in temperate climates, and in the dry season in tropical climates. Most noteworthy is the "meningitis belt" of sub-Saharan Africa where the majority of cases occur from December to June. For further information, refer to the Committee to Advise on Tropical Medicine and Travel (CATMAT) website.
Spectrum of clinical illness
IMD is characterized by a short incubation period (2 to 10 days, usually 3 to 4 days) and usually presents as an acute febrile illness with rapid onset and features of meningitis or septicemia (meningococcemia), or both, and a characteristic non-blanching petechial or purpuric rash. Symptoms of meningitis include intense headache, fever, nausea, vomiting, photophobia and stiff neck. Meningococcemia is characterized by circulatory collapse, hemorrhagic skin rash and a high fatality rate. Overall mortality is approximately 10%, and 10% to 20% of survivors have long term sequelae which include hearing loss, neurologic disabilities, and digit or limb amputations.
IMD occurs sporadically worldwide and in focal epidemics. In Canada, IMD is endemic and reported year round with peaks in winter. Although people at any age can develop IMD, children younger than 5 are at the greatest risk, followed by people aged 15-19 years and 60 years and up. Serogroups B, C, W-135 and Y are most commonly reported types in the country.
With the introduction of childhood immunization programs against serogroup C IMD in 2002, not unexpectedly, the incidence of serogroup C has decreased significantly over the years. While the incidence of serogroup B remains predominant, disease caused by serogroup W-135 and Y have stabilized at relatively lower incidence rates.
For more information about IMD distribution in Canada, refer to the PHAC website. Comprehensive updates on the epidemiology of IMD in Canada are published periodically in the Canada Communicable Disease Report (CCDR).
Monovalent conjugate meningococcal vaccines (Men-C-C)
Quadrivalent conjugate meningococcal vaccines (Men-C-ACYW)
Quadrivalent polysaccharide meningococcal vaccine (Men-P-ACYW-135)
Multicomponent meningococcal vaccine (4CMenB)
For complete prescribing information, consult the product leaflet or information contained within the product monograph available through the Health Canada's Drug Product Database. Refer to Contents of Immunizing Agents Available for Use in Canada in Part 1 for a list of all vaccines available for use in Canada and their contents.
A study of Men-C-C vaccine demonstrated effectiveness in infants of 97% within one year of vaccination, decreasing to 68% after 1 year. Longer term vaccine effectiveness requires receipt of a booster dose in the second year of life for those immunized in infancy. Vaccine effectiveness of Men-C-ACYW-DT within 3 to 4 years of vaccination in adolescence is 80% to 85%; however, effectiveness wanes over time. There is no efficacy or effectiveness data available for Men-C-ACYW-CRM, Men-C-ACYW-TT or 4CMenB. Vaccine effectiveness measured at the individual level may under-estimate the impact of the immunization programs on the burden of meningococcal disease in the community, due to the additional benefit conferred by herd immunity.
Men-C-C and Men-C-ACYW vaccines are immunogenic in infants and toddlers but those vaccinated in infancy show a waning immune response over time. Vaccination with conjugate meningococcal vaccine primes the immune system for memory and induces good anamnestic responses; however, anamnestic response may not be sufficient to prevent disease after exposure and circulating antibodies are thought to be essential. In comparison to polysaccharide meningococcal vaccine, conjugate meningococcal vaccines demonstrate greater immunogenicity and induce better immunologic memory. Conjugate meningococcal vaccines do not result in hyporesponsiveness and have been shown to overcome the hyporesponsiveness evident with polysaccharide meningococcal vaccine usage. In clinical trials, the 4CMenB vaccine has shown to be immunogenic in toddlers and children after at least two doses, and in adolescents and adults after one dose.
Infants may receive Men-C-C vaccine beginning at 2 months of age, depending on the provincial and territorial schedule and the incidence of meningococcal serogroup C disease in their jurisdiction. Men-C-C vaccine is recommended for all children at 12 to 23 months of age, regardless of any doses given during the first year of life. It is routinely given at 12 months and is recommended in unimmunized children less than 5 years of age. Men-C-C vaccine may be considered for children 5 to 11 years of age if they have not previously been immunized as infants or toddlers. In addition, immunization with 4CMenB vaccine may be considered on an individual basis, for children two months of age and older, to protect against IMD caused by serogroup B strains expressing antigens covered by the vaccine.
Either Men-C-C or Men-C-ACYW vaccine, depending on local epidemiology and programmatic considerations, is recommended for adolescents, routinely at 12 years of age and young adults, even if they have previously been vaccinated as an infant or toddler. In addition, 4CMenB vaccine may be considered on an individual basis, depending on the preferences of the vaccine recipient, regional serogroup B IMD incidence and strain susceptibility to 4CMenB vaccine, for protection against serogroup B strains expressing antigens covered by the vaccine.
Individuals with increased risk of meningococcal disease because of underlying medical conditions are as follows:
Table 3 outlines the recommended schedule for vaccination of individuals who are at high risk due to underlying medical conditions. Refer to Booster doses and re-immunization section for additional information.
Either Men-C-ACYW, 4CMenB, or both vaccines are recommended for individuals at increased risk of exposure to meningococcal disease as follows:
Meningococcal vaccine is also recommended for most close contacts of a case of IMD and for outbreak control, if the disease is caused by a serogroup contained in the vaccine. Refer to Post-exposure management and Outbreak control for additional information.
2 to 23 months of age
Based on available published data in this age group, Men-C-ACWY-CRM should be used because it has been found to be safe and immunogenic. Routine meningococcal C conjugate vaccine does not need to be administered in addition to Men-C-ACWY-CRM. For toddlers and children who may be at increased high risk of IMD caused by serogroup B, 4CMenB vaccine should also be considered.
24 months to 55 years of age
Any of the Men-C-ACYW vaccines may be used. For individuals who are at high risk of IMD caused by serogroup B, 4CMenB vaccine should also be considered.
56 years of age and older
Any of the Men-C-ACYW vaccines should be considered. For individuals who are at high risk of IMD caused by serogroup B, 4CMenB vaccine should also be considered.
Refer to Schedule for additional information, Table 1 for recommended vaccination for certain travellers and Table 3 for recommended vaccination of high risk individuals with underlying medical conditions.
Children and adults lacking adequate documentation of immunization should be considered unimmunized and started on an immunization schedule appropriate for their age and risk factors. Conjugate meningococcal vaccine, as appropriate for age, may be given regardless of possible previous receipt of the vaccine, as adverse events associated with repeated immunization have not been demonstrated. Refer to Immunization of Children and Adults with Inadequate Immunization Records in Part 3 for additional general information.
Conjugate meningococcal vaccines have not been studied in pregnancy; however, there is no theoretical reason to suspect that adverse events will occur and, in circumstances in which the benefits outweigh the risks, the use of conjugate meningococcal vaccines in pregnancy may be considered. Inactivated vaccines, such as conjugate or multicomponent meningococcal vaccines, may be administered to women who are breastfeeding. Refer to Immunization in Pregnancy and Breastfeeding in Part 3 for additional general information.
Premature infants in stable clinical condition should be immunized with conjugate meningococcal vaccine at the same chronological age and according to the same schedule as full-term infants. Infants born prematurely, especially those weighing less than 1,500 grams at birth are at higher risk of apnea and bradycardia following vaccination. Hospitalized premature infants should have continuous cardiac and respiratory monitoring for 48 hours after their first immunization. Refer to Immunization of Infants Born Prematurely in Part 3 for additional general information.
Residents of long-term care facilities should receive meningococcal vaccine as appropriate for their risk factors. Refer to Immunization of Patients in Health Care Institutions in Part 3 for additional general information.
Quadrivalent conjugate meningococcal vaccine is recommended for certain high risk individuals as outlined under High risk groups above. 4CMenB vaccine should also be considered for individuals who are at high risk of IMD caused by serogroup B strains expressing antigens covered by the vaccine. When considering immunization of an immunocompromised person, consultation with the individual's attending physician may be of assistance in addition to the guidance provided below. For complex cases, referral to a physician with expertise in immunization or immunodeficiency is advised.
Persons with complement, properdin, factor D or primary antibody deficiencies should be vaccinated with Men-C-ACYW vaccine. Refer to Table 3 for additional information.
Hematopoietic stem cell transplantation (HSCT- autologous or allogeneic)
For children and adults, the effect of any previous meningococcal vaccine will be diminished following HSCT; therefore, HSCT recipients should be vaccinated as per recommendations for the previously unvaccinated based on their age or risk factors for IMD. If routinely indicated based on age or other risk factors, conjugate meningococcal vaccine can be given as early as 6 months after transplantation, unless needed earlier for management of a close contact or outbreak. However, if it is given earlier than 6 months after transplant the response may not be optimal and consideration should be given to repeating the dose at least 6 months after transplant (and at least 8 weeks after the previous dose) if ongoing protection is needed.
Solid organ transplantation
Conjugate meningococcal vaccine (type of vaccine as appropriate for age) is recommended to be given at least two weeks before transplantation if it is routinely indicated based on age or risk factors for IMD. If not given prior to transplant and routinely indicated based on age or other risk factors, meningococcal vaccine can be given any time after 6 months post-transplant and at least one month after discontinuation of treatment for acute rejection unless needed earlier for management of a close contact or outbreak. However, if it is given earlier than 6 months after transplant or earlier than 1 month after discontinuing treatment for acute rejection, the response may not be optimal and consideration should be given to repeating the dose at least 6 months after transplant and at least 1 month after discontinuing treatment for acute rejection (and at least 8 weeks after the previous dose) if ongoing protection is needed.
Two doses of Men-C-ACYW vaccine should be considered for individuals with HIV infection. Refer to Table 3 for additional information.
Acquired complement deficiency
People with conditions such as paroxysmal nocturnal hemoglobinuria who are receiving the terminal complement inhibitor eculizumab (Soliris™) should receive two doses of Men-C-ACYW vaccine. They must be vaccinated at least two weeks prior to receiving the first dose of eculizumab, if possible, and every 5 years thereafter if they continue to use the drug. Refer to Table 3 for additional information.
Two doses of Men-C-ACYW vaccine are recommended for persons with anatomic or functional asplenia, including sickle cell disease. When elective splenectomy is planned, all recommended vaccines should ideally be completed at least 2 weeks before surgery; if only one dose can be given before surgery, the second dose should be given 8 weeks after the first dose, with a minimum interval of 4 weeks. In the case of an emergency splenectomy, two doses of vaccine should ideally be given beginning 2 weeks after surgery but can be given earlier, before discharge, if the person might not return for vaccination after discharge. Persons one year of age and older with asplenia who have not received Men-C-ACYW vaccine should receive two doses administered 8 weeks apart, with a minimum interval of 4 weeks. Periodic booster doses with Men-C-ACYW vaccine are also recommended. In addition, 4CMenB vaccine should be considered for individuals who are at high risk of IMD caused by serogroup B.
Refer to Table 3 for vaccination recommendations of high risk individuals due to underlying conditions based on age. Refer to Booster doses and re-immunization for additional information and Immunization of Persons with Chronic Diseases in Part 3 for additional general information.
Travellers should be vaccinated with Men-C-ACYW, 4CMenB or both vaccines, depending on the risk of meningococcal disease in the area of travel. Men-C-C vaccine alone is not appropriate for protection of travellers, as it does not protect against serogroup A, which is endemic in selected regions of the world (e.g. sub-Saharan Africa), or serogroup W-135 disease. 4CMenB vaccine is recommended for individuals travelling to an area with a hyperenedemic strain or an outbreak that is known to be caused by a serotype B that can be prevented by the vaccine. Current meningococcal disease outbreak information is available from the WHO at: http://www.who.int/csr/don/archive/disease/meningococcal_disease/en/.
Refer to Table 1 for recommended immunization for travellers to destinations where risk of meningococcal transmission is high.
Proof of meningococcal immunization may be required by certain countries. For example, Saudi Arabia requires proof of immunization with a quadrivalent vaccine for pilgrims to the Hajj in Mecca (refer to http://www.moh.gov.sa/en/Hajj/Pages/default.aspx). For travel to the Hajj, re-immunization at an interval of less than 5 years from the last dose may be required. Refer to Immunization of Travellers in Part 3 for additional general information.
Refer to the CATMAT information on assessing a traveller's need for pre-travel vaccination.
|Age||Recommended vaccine(s)||ScheduleTable 1 - Footnote 1, Table 1 - Footnote 2|
|2 to 11 months of age||Men-C-ACYW-CRM or 4CMenB||2 or 3 dosesTable 1 - Footnote 3 given 8 weeks apart (with another dose between 12-23 months of age that is at least 8 weeks from the previous dose)Table 1 - Footnote 4|
|12 to 23 months of age||Men-C-ACYW-CRM or 4CMenB||2 doses at least 8 weeks apartTable 1 - Footnote 4|
|24 months to 10 years of age||Men-C-ACYW or 4CMenB||1 dose of Men-C-ACYW; 2 doses of 4CMenB given at least 8 weeks apart|
|11 years of age and olderTable 1 - Footnote 5||Men-C-ACYW or 4CMenB||1 dose of Men-C-ACYW; 2 doses of 4CMenB given at least 4 weeks apart|
Health care providers who see persons newly arrived in Canada should review the immunization status and update immunization for these individuals. Review of meningococcal vaccination status is particularly important for persons from areas of the world where sickle cell disease is present as persons with sickle cell disease are at risk of serious meningococcal infections. In many countries outside of Canada, conjugate meningococcal vaccines are in limited use. Information on vaccination schedules in other countries can be found on the following website:
Refer to Immunization of Persons New to Canada in Part 3 for additional general information.
Research, industrial and clinical laboratory personnel who are potentially routinely exposed to N. meningitidis should be offered one dose of either Men-C-ACYW, 4CMenB or both vaccines. Re-vaccination is generally recommended every 5 years for Men-C-ACYW. Routine infection control precautions should be practiced at all times to minimize the risk of exposure in laboratory workers and post-exposure prophylaxis should be offered after recognized exposures. Refer to Booster doses and re-immunization for additional information.
Health care workers (HCW)
Nosocomial transmission of IMD is very uncommon. HCW are considered as close contacts only if they have had intensive, unprotected contact (without wearing a mask) with infected patients (e.g., intubating, resuscitating or closely examining the oropharynx). It is recommended that HCW use barrier precautions to avoid direct contact with respiratory secretions of patients with meningococcal disease until the patient has completed 24 hours of effective antibiotic therapy, according to provincial and territorial communicable disease control guidelines.
There is no evidence to recommend routine meningococcal immunization of HCW since the risk period for acquisition ends when contact with an untreated patient terminates, and antibiotic chemoprophyalxis should be sufficient in the high-risk situation described above.
Military personnel may be at increased risk when accommodated in close quarters or through deployment to endemic or epidemic countries.
Refer to Immunization of Workers in Part 3 for additional general information.
Contacts of cases
Close contacts of individuals with meningococcal infections have an increased risk of developing IMD; this risk is greatest for household contacts. The increased risk of disease for household contacts persists for up to 1 year after disease in the index case and beyond any protection from antibiotic chemoprophylaxis. In general, this prolonged risk is not seen in contacts who do not have ongoing exposure.
Chemoprophylaxis should be offered to all persons having close contact with a case of IMD from 7 days before onset of symptoms in the case to 24 hours after onset of effective treatment in the case, regardless of their immunization status. Refer to the PHAC Guidelines for the Prevention and Control of Meningococcal Disease for information about chemoprophylaxis in the management of close contacts of individuals with meningococcal infection.
Vaccination or re-vaccination of certain close contacts should be considered in addition to chemoprophylaxis when the serogroup is vaccine preventable, as it may further reduce the risk of subsequent meningococcal disease.
Close contacts requiring chemoprophylaxis and consideration for immunoprophylaxis
The following individuals (regardless of immunization status) should receive chemoprophylaxis and, if the meningococcal serogroup identified in the case of IMD is vaccine preventable, should also be considered for immunoprophylaxis:
Refer to Table 2 for specific recommendations for immunoprophylaxis of close contacts of IMD cases according to the serogroup in the index case and the age and underlying conditions of the contact.
Re-vaccination criteria for those previously vaccinated against IMD
The following provides criteria for the re-vaccination of previously vaccinated close contacts when the index case has a vaccine preventable IMD serogroup or there is a vaccine preventable outbreak of IMD:
Close contacts requiring chemoprophylaxis only
The following individuals should receive chemoprophylaxis only, immunoprophylaxis is not necessary:
Outbreaks of meningococcal disease
Consultation with public health officials, experts in communicable disease, or both is important in the assessment and control of meningococcal disease outbreaks. Outbreaks may be controlled by the use of a conjugate meningococcal vaccine. The type of vaccine to use in an outbreak is dependent on the serogroup causing the outbreak and the age of those being vaccinated as outlined in Table 2. Re-vaccination criteria of previously vaccinated individuals are outlined above in Re-vaccination criteria for those previously vaccinated against IMD.
Close contacts and outbreak control of serogroup C invasive meningococcal disease
2 months to less than 12 months of age
Unvaccinated: 1 dose immediately after exposure then complete the routine series of Men-C-C
Previously vaccinated: If previously vaccinated then re-vaccinate with Men-C-C if at least 4 weeks have elapsed since last dose, then complete the routine series of Men-C-C if necessary
12 months - 10 years of age
Unvaccinated: 1 dose immediately after exposure
Previously vaccinated: If previously vaccinated at less than 1 year of age OR person is at high risk for IMD due to underlying medical conditionsTable 2 - Footnote 1, then re-vaccinate with one dose of Men-C-C if at least 4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose
11 years of age and older
Unvaccinated: 1 dose immediately after exposure
Previously vaccinated: If previously vaccinated at less than 1 year of age OR person is at high risk for IMD due to underlying medical conditionsTable 2 - Footnote 1, then re-vaccinate with one dose of vaccine of choice if at least 4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose
Close contacts and outbreak control of serogroup A, Y, or W-135 invasive meningococcal disease
2 months to less than 12 months of age
Unvaccinated: 2 or 3 doses given 8 weeks apart with another dose between 12 and 23 months and at least 8 weeks from the previous dose
12 to 23 months of age
Unvaccinated: 2 doses at least 8 weeks apart
2 years and older
Unvaccinated: 1 dose immediately after exposureTable 2 - Footnote 3
Close contacts and outbreak control of serogroup B invasive meningococcal diseaseTable 2 - Footnote 4
|2 months to less than 6 months||4CMenB||
Unvaccinated: 1 dose immediately after exposureTable 2 - Footnote 5; then re-vaccinate with 2 more doses with at least a 4 week interval between doses.
Previously vaccinated: 1 dose immediately after exposureTable 2 - Footnote 5
|6 months to less than 11 years||4CMenB||
Unvaccinated: 1 dose immediately after exposureTable 2 - Footnote 5; then re-vaccinate with a single dose after at least 8 weeks.
Previously vaccinated: 1 dose immediately after exposureTable 2 - Footnote 5
|11 years and older||4CMenB||
Unvaccinated: 1 dose immediately after exposureTable 2 - Footnote 5; then re-vaccinate with a single dose after at least 4 weeks.
Previously vaccinated: 1 dose immediately after exposureTable 2 - Footnote 5
Each dose of meningococcal vaccine is 0.5 mL.
Route of administration
Conjugate meningococcal vaccine should be administered intramuscularly (IM). Refer to Vaccine Administration Practices in Part 1 for additional information.
Recommended meningococcal immunization schedules and products vary across provinces and territories, depending upon the epidemiology of meningococcal disease in the jurisdiction and other programmatic factors.
Healthy infants and children (2 to 23 months of age)
Men-C-C vaccine should be provided to healthy infants according to provincial and territorial schedules. If Men-C-C vaccine is given to infants less than 12 months of age, a booster dose should be given between 12 to 23 months of age. If the booster dose is missed, it can be given at the next vaccination opportunity.
Healthy children, adolescents and young adults
One dose of Men-C-C vaccine is recommended for previously unimmunized children 12 months to less than 5 years of age and may be considered for children 5 to 11 years of age. In addition to routine Men-C-C vaccine for infants, and young children, adolescents and young adults (12 to 24 years of age) should receive one dose of either Men-C-C or Men-C-ACYW vaccine, based on local epidemiology and programmatic considerations, with around 12 years being the preferred age for the routine dose.
High risk individuals due to underlying medical conditions
High risk individuals are those with underlying conditions that make them more likely to develop IMD. Schedule options for high risk individuals who have not previously received a quadrivalent conjugate or multicomponent meningococcal vaccine are included in Table 3. As noted in Table 3, previously unimmunized high risk persons 12 months of age and older should receive a two dose primary series administered 8 weeks apart, with a minimum interval of 4 weeks.
|Age||Recommended vaccine(s)||ScheduleTable 3 - Footnote 3|
|2 to 11 months of age||Men-C-ACYW-CRM and 4CMenB||2 or 3 dosesTable 3 - Footnote 4 given 8 weeks apart (with another dose between 12-23 months of age that is at least 8 weeks from the previous dose)Table 3 - Footnote 3|
|12 to 23 months of age||Men-C-ACYW-CRMTable 3 - Footnote 2 and 4CMenB||2 doses at least 8 weeks apartTable 3 - Footnote 5|
|24 months to 10 years of age||Men-C-ACYW and 4CMenB||2 doses at least 8 weeks apartTable 3 - Footnote 5|
|11 years of age and olderTable 3 - Footnote 6||Men-C-ACYWTable 3 - Footnote 5 and 4CMenB||2 doses of Men-C-ACYW-CRM 8 weeks apartTable 3 - Footnote 5; 2 doses of 4CMenB given at least 4 weeks apart|
Circulating antibodies are considered necessary to protect an individual against IMD. Re-vaccination is recommended as follows:
People previously vaccinated with a polysaccharide meningococcal vaccine should be re-vaccinated with the appropriate conjugate or multicomponent meningococcal vaccine if they remain at ongoing risk for meningococcal disease, with at least a 6 month interval following vaccination with polysaccharide meningococcal vaccine. The need for and timing of 4CMenB booster doses has not yet been determined.
Serologic testing is not recommended before or after receiving meningococcal vaccine.
Menactra®, NeisVac-C®: Store in a refrigerator at +2°C to +8°C. Do not freeze.
Bexsero®, Menjugate®, Menveo™, Nimenrix®: Store in a refrigerator at +2°C to +8°C. Do not freeze. Protect from light.
Refer to Storage and Handling of Immunizing Agents in Part 1 for additional general information.
Men-C-C vaccine may be administered concomitantly with routine childhood vaccines, and Men-C-ACYW vaccine may be administered concomitantly with adolescent and adult age appropriate vaccines at different injection sites using separate needles and syringes. The immune response to routine infant vaccines and the 4CMenB vaccine does not appear to be affected when these vaccines are administered simultaneously.
Men-C-ACYW-CRM can be administered with routine paediatric vaccines; however, further studies are needed with regard to concomitant administration with pneumococcal 13-valent conjugate vaccine. Co-administration of Men-C-ACYW-CRM and combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) may result in a lower immune response to the pertussis antigens than when Tdap vaccine is given alone; however, the clinical significance of this is unknown. Tdap vaccine given one month after Men-C-ACYW-CRM induces the strongest immunologic response to pertussis antigens. Refer to Timing of Vaccine Administration in Part 1 for additional general information.
Injection site reactions occur in up to 59% of vaccinees. Fever is reported in up to 5% of recipients and systemic reactions, such as headache and malaise, are reported in up to 60% of recipients.
Mild reactions, including injection site reactions (redness, tenderness, and swelling), occur in up to 50% of vaccine recipients. Irritability occurs in up to 80% of infants and fever in up to 9% when other vaccines were administered. Headaches and malaise occur in up to 10% of older children and adults. These reactions last no more than a few days.
Solicited local and systemic reactions have been commonly reported in clinical trials and include tenderness, induration, sleepiness and irritability. Higher rates of fever have been observed with simultaneous administration of 4CMenB vaccine and routine infant vaccines; therefore, routine prophylactic administration of acetaminophen or separating 4CMenB vaccination from routine vaccination schedule has been proposed for preventing fever in infants and children up to three years of age.
Serious adverse events are rare following immunization and, in most cases, data are insufficient to determine a causal association.
Vaccine providers are asked to report, through local public health officials, any serious or unexpected adverse event felt to be temporally related to vaccination. An unexpected AEFI is an event that is not listed in available product information but may be due to the immunization, or a change in the frequency of a known AEFI. Refer to Box 1 in Vaccine Safety in Part 2 and Reporting Adverse Events Following Immunization (AEFI) in Canada for additional information about AEFI reporting.
Meningococcal vaccine is contraindicated in persons with a history of anaphylaxis after previous administration of the vaccine and in persons with proven immediate or anaphylactic hypersensitivity to any component of the vaccine or its container. Refer to Table 1 in Contents of immunizing agents available for use in Canada in Part 1 for lists of all vaccines available for use in Canada and their contents. For meningococcal vaccines, potential allergens include:
There are very few individuals who cannot receive meningococcal vaccines. In situations of suspected hypersensitivity or non-anaphylactic allergy to vaccine components, investigation is indicated, which may involve immunization in a controlled setting. Consultation with an allergist is advised. Men-P-ACYW-135 may be considered in the rare circumstance that someone is allergic to components other than latex in the conjugate meningococcal vaccines.
Administration of meningococcal vaccine should be postponed in persons with moderate or severe acute illness. Persons with minor acute illness, with or without fever, may be vaccinated.
Refer to Contraindications and Precautions in Part 2 for additional general information.
There are no published data regarding the interchangeability of Men-C-C vaccines, but the vaccines have been safely interchanged without a noticeable decrease in efficacy. When possible, the infant series should be completed with the same vaccine. Either Men-C-ACYW vaccine may be used for re-vaccination, regardless of which meningococcal vaccine was used for initial vaccination. Refer to Principles of Vaccine Interchangeability in Part 1 for additional general information.
Meningococcal B Pilot Project Task Group. The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada: Common Guidance Statement. Public Health Agency of Canada. March 2014 (Catalogue no. HP40-103/2014E-PDF).
National Advisory Committee on Immunization (NACI).Update on quadrivalent meningococcal vaccines available in Canada. Public Health Agency of Canada. October 2014 (Catalogue no. HP40-125/2014E-PDF).